Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle
17 May 2017
Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.
Epic Sciences nets $40M for cancer liquid biopsy
02 May 2017
Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.
Biopharma just can’t get enough of Epic Sciences
02 May 2017
Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.
With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer
02 May 2017
When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well a cancer patient is responding to specific anti-cancer drug regimens.
Corneal inlays need your boost to hit their stride
10 April 2017
Recently, ReVision Optics announced the implantation of the 1,000th Raindrop corneal inlay in the United States since its approval last August. The AcuFocus Kamra corneal inlay, which was approved earlier, has now reached nearly 4,000 U.S. implants, according to a source at the company.
New help for that bane of middle-age: blurry close-up vision
07 March 2017
Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who's really a good candidate to toss their specs?
Atlas to invest in extra capacity at STI test manufacturing partner Bespak
16 February 2017
Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.
Liquid biopsies: The next frontier in cancer?
15 February 2017
As immuno-oncology dazzles and pharma companies race to develop new cancer medicines, a similar boom is underway to speed up and improve the detection of cancers.
Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio
01 February 2017
The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of the global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.
Struggling Marinus gets a bump out of a positive PhII snapshot
24 January 2017
A little more than six months since its stock price was crushed by a failed late-stage program for its leading — and only — drug, tiny biotech microcap Marinus $MRNS saw its shares shoot up this morning after it offered a positive Phase II snapshot on a handful of patients who suffer from a rare genetic ailment.
As vaccine makers gear up for a busy season, Seqirus exec says influenza is poised for a return
18 August 2022
A low-toxic plant-based medicine for type 2 diabetes has been patented in the Russian Federation
18 August 2022
Copper coated surfaces found to reduce COVID-19 transmission
17 August 2022
Does terminal sterilisation affect the quality of ophthalmic APIs?
17 August 2022